Smith & Nephew pays $782 million to acquire Healthpoint Biotherapeutics, hoping to enhance its position in bioactives.
Smith & Nephew (FTSE:SN, NYSE:SNN) completed the acquisition of substantially all the assets of Healthpoint Biotherapeutics, paying $782 million in cash financed by the company's existing cash resources and bank facilities.
The purchase of Healthpoint gives Smith & Nephew a strong position in bioactives, the fastest growing area of advanced wound management, according to the press release.
"We are delighted to welcome Healthpoint to Smith & Nephew," CEO Olivier Bohuon said in prepared remarks. "Its bioactives platform perfectly complements our exudate and infection management and negative pressure expertise."
U.K.-based Smith & Nephew in November announced intentions to acquired privately held Healthpoint, which has strong positions in bioactive debridement, dermal repair and regeneration products, which collectively drew $190 million in revenues during 2012, Smith & Nephew noted.
Bohuon said the company's Advanced Wound Management division has consistently outperformed the market growth rate in recent years and the deal will help customers meet the growing human and economic cost of wounds.
The FDA plans a public workshop on robotically-assisted surgical devices to solicit feedback on how...
Regdy blog's Andrew Ahn discusses the advantages of getting your device approved by FDA.
EndoChoice says it raised $57 million from a syndicate of prior and new backers it plans to use boost...
Europe's top court rules that Boston Scientific must cover the cost of replacing defective pacemakers...
Medtronic invests in anti-leg-cramp drug maker Flex Pharma's initial public offering.